Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at Weeks 52 and 76 SOL-1 trial Week 36 primary endpoint data now expected in 1Q 2026 due to requirement for masking until Week 52 to allow for re-dosing Inclusion of re-dosing in SOL-1, along with exceptional retention seen to date in the study, paves way for reduction of SOL-R trial size to 555 subjects (previously 825), potentially accelerating registration timelines Additional updates provided on SOL-R non-inferiority margin and rescue criteria Cash balance of $392.1M as of December 31, 2024, expected to fund operations into 2028 and the Company currently...

KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer’s disease agitation expected by the end of 2025 Expect to progress next M4 positive allosteric modulator (PAM) program into the clinic by mid-2025 Strong financial position with $307.6 million in cash, cash equivalents and marketable securities expected to support operations into mid-2026 WATERTOWN, Mass., March 03, 2025 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including two clinical-stage programs, today announced financial results for the fourth quarter and full year ended December 31,...

— LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line with preliminary results published January 8 — Reiterates 2025 guidance, with the number of patients on LUMRYZ expected to increase to 3,300-3,500 by year-end, generating $240-$260 million in net product revenue and cash flow of $20-40 million — Executing multiple initiatives to accelerate patient demand for LUMRYZ — Patient enrollment is on track in the Phase 3 REVITALYZ™ study to evaluate efficacy and safety of LUMRYZ in Idiopathic Hypersomnia (IH) — Avadel management to host a conference call today at 8:30 a.m. ET DUBLIN, March 03, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming...

– $7.7 million in Revuforj® (revumenib) net product revenue in initial five weeks of launch – – Launched Niktimvo™ (axatilimab-csfr) in the U.S. in late January, in partnership with Incyte – – sNDA filing for revumenib in R/R mNPM1 AML expected in 2Q25 based on positive pivotal data from AUGMENT-101 trial – – $692.4 million in cash, cash equivalents and investments expected to fund the company to profitability – – Company to host a conference call today at 8:00 a.m. ET – NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “We are off to a strong start with the U.S....

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le Initiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously treated with at least one topoisomerase-1 inhibitor (topo-1) ADC Plan to present additional clinical data from dose escalation and backfill cohorts in 2025 Conference call today at 8:00 a.m. ETCAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024. “We made significant progress advancing the...

Fortified balance sheet, optimized operations, disciplined growth initiatives, and strategic hires set foundation for 2025 12,300 MW development pipeline with 2,800 MW under exclusivity as of December 31, 2024 Earnings Release HighlightsFull year 2024 revenue of $162.4 million, net income of $331.4 million, and Adjusted EBITDA of $555.7 million. Fourth quarter 2024 energy cost per megawatt-hour (“MWh”) of $31.63, a 30% decrease from the fourth quarter of 2023. Total energy capacity under management of 1,020 megawatts (“MW”) as of December 31, 2024. 12,300 MW development pipeline with 2,800 MW of capacity under exclusivity as of December 31, 2024. Strategic Bitcoin reserve of 10,171 Bitcoin with a market value of $949.5 million as of December 31, 2024.MIAMI, March 03, 2025 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut...

For the three months and full-year ended December 31, 2024, from continuing operations:Revenues of $697.0 million for the fourth quarter, $2,696.4 million for the full year GAAP net loss of $(73.9) million for the fourth quarter, $(271.5) million for the full year Adjusted EBITDA of $56.0 million for the fourth quarter, $202.5 million for the full year Fourth-quarter book-to-bill ratio of 1.35xDURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the fourth quarter and full year ended December 31, 2024. “Our intense focus on our customers’ success and creating a better customer experience has resulted in the stronger demand that is reflected in this quarter’s book-to-bill,” said Tom Pike, chairman...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by positive APG990 interim Phase 1 results, which exceeded trial objectives and demonstrated potential for three- and six-month dosing in combination with APG777; APG279 readout expected in second half of 2026 $731.1 million cash, cash equivalents and marketable securities with runway into Q1 2028 SAN FRANCISCO and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets,...

Preliminary Statement of Results for the year ended 31 December 2024 Irish Continental Group (ICG), the leading Irish-based maritime transport group, reports its financial performance for the year ended 31 December 2024. HighlightsFinancial Summary          2024 2023 Change  Revenue   €603.8m €572.0m +5.6%  EBITDA   €133.5m €132.6m +0.7%  Operating profit   €69.1m €68.4m +1.0%  Basic earnings per share   36.3c 36.2c ...

EXOSENS DELIVERS VERY STRONG FULL-YEAR 2024 RESULTS, OVERPERFORMING ON ITS IPO GUIDANCE SUSTAINED GROWTH DYNAMIC ANTICIPATED FOR 2025-2026 FY 2024 HIGHLIGHTSStrong revenue growth of +35.0%, above IPO guidance, to €394.1m in 2024, reflecting dynamic like-for-like growth (+24.9%) and successful integration of bolt-on acquisitions Significant increase in profitability, with adjusted EBITDA of €118.5m in 2024 (+37.8%), representing a best-in-class margin of 30.1% (vs. 29.5% in 2023), above IPO guidance and above top range of estimated landing given in January 2025 Net profit of €30.7m in 2024, recording a strong growth of +66.7% over 2023 Robust balance sheet with a net leverage of 1.2x at year-end 2024, enabling the execution of our growth strategy Proposed payment of a €0.10 cash dividend per share for the 2024 fiscal year, for the first...